Wijnand Helfrich

4.5k total citations
114 papers, 3.7k citations indexed

About

Wijnand Helfrich is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Wijnand Helfrich has authored 114 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 45 papers in Radiology, Nuclear Medicine and Imaging and 44 papers in Oncology. Recurrent topics in Wijnand Helfrich's work include Monoclonal and Polyclonal Antibodies Research (30 papers), Immunotherapy and Immune Responses (24 papers) and CAR-T cell therapy research (24 papers). Wijnand Helfrich is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (30 papers), Immunotherapy and Immune Responses (24 papers) and CAR-T cell therapy research (24 papers). Wijnand Helfrich collaborates with scholars based in Netherlands, United States and Germany. Wijnand Helfrich's co-authors include Edwin Bremer, Marco de Bruyn, Douwe F. Samplonius, Lou de Leij, Valerie R. Wiersma, Igle J. de Jong, Hildo J.K. Ananias, Lou F. M. H. de Leij, Bram ten Cate and Grietje Molema and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Nature Biotechnology.

In The Last Decade

Wijnand Helfrich

112 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wijnand Helfrich Netherlands	38	1.7k	1.4k	1.2k	998	389	114	3.7k
Sophia N. Karagiannis United Kingdom	37	1.2k 0.7×	1.8k 1.3×	1.3k 1.1×	941 0.9×	257 0.7×	127	4.0k
Rishi Surana United States	15	1.3k 0.8×	858 0.6×	1.8k 1.5×	634 0.6×	409 1.1×	24	3.4k
Patrizia Castellani Italy	37	2.0k 1.2×	1.1k 0.8×	1.1k 1.0×	1.4k 1.4×	308 0.8×	107	4.6k
Pamela A. Trail United States	29	1.7k 1.0×	474 0.3×	1.5k 1.2×	1.2k 1.2×	331 0.9×	61	3.7k
Kin-Ming Lo United States	27	1.8k 1.1×	1.1k 0.8×	1.4k 1.2×	789 0.8×	275 0.7×	43	3.5k
Delia Mezzanzanica Italy	37	2.0k 1.2×	1.0k 0.8×	1.3k 1.1×	897 0.9×	242 0.6×	107	3.9k
Klára Tótpál United States	29	3.5k 2.1×	2.1k 1.6×	1.7k 1.4×	1.5k 1.5×	209 0.5×	59	5.3k
Uwe Zangemeister‐Wittke Switzerland	44	4.0k 2.3×	1.0k 0.8×	1.6k 1.4×	866 0.9×	428 1.1×	108	5.6k
Margareta M. Mueller Germany	31	1.8k 1.0×	972 0.7×	1.7k 1.5×	517 0.5×	380 1.0×	48	4.6k
Paul J. Yazaki United States	33	1.3k 0.8×	461 0.3×	1.1k 0.9×	1.7k 1.7×	439 1.1×	102	3.4k

Countries citing papers authored by Wijnand Helfrich

Since Specialization

Citations

This map shows the geographic impact of Wijnand Helfrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wijnand Helfrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wijnand Helfrich more than expected).

Fields of papers citing papers by Wijnand Helfrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wijnand Helfrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wijnand Helfrich. The network helps show where Wijnand Helfrich may publish in the future.

Co-authorship network of co-authors of Wijnand Helfrich

This figure shows the co-authorship network connecting the top 25 collaborators of Wijnand Helfrich. A scholar is included among the top collaborators of Wijnand Helfrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wijnand Helfrich. Wijnand Helfrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Ke, Xiurong, et al.. (2023). Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells. OncoImmunology. 12(1). 2207868–2207868. 3 indexed citations

2.

Ke, Xiurong, et al.. (2023). A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer. Cancers. 15(14). 3651–3651. 2 indexed citations

3.

Antunes, Inês F., Aren van Waarde, Rudi Dierckx, et al.. (2021). Synthesis and Evaluation of ¹⁸F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-¹⁸F-Fluoro-5α-Dihydrotestosterone. Journal of Nuclear Medicine. 62(8). 1140–1145. 8 indexed citations

4.

Boer, H. Rudolf de, Marieke Everts, Douwe F. Samplonius, et al.. (2018). Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene. 38(9). 1477–1488. 10 indexed citations

5.

Bruyn, Marco de, Valerie R. Wiersma, Maartje C.A. Wouters, et al.. (2015). CD20⁺T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. OncoImmunology. 4(4). e999536–e999536. 25 indexed citations

6.

Hristodorov, Dmitrij, Radoslav Mladenov, Judith Niesen, et al.. (2014). EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein. Molecular Cancer Therapeutics. 13(9). 2194–2202. 18 indexed citations

7.

Holley, Janet E., Edwin Bremer, Alexandra C. Kendall, et al.. (2014). CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Multiple Sclerosis and Related Disorders. 3(5). 650–658. 56 indexed citations

8.

Lütje, Susanne, Mark Rijpkema, Wijnand Helfrich, Wim J.G. Oyen, & Otto C. Boerman. (2014). Targeted Radionuclide and Fluorescence Dual-modality Imaging of Cancer: Preclinical Advances and Clinical Translation. Molecular Imaging and Biology. 16(6). 747–755. 51 indexed citations

9.

Lütje, Susanne, Gerben M. Franssen, Wijnand Helfrich, et al.. (2012). Targeting human prostate cancer xenografts with In-111-labeled D2B IgG, F(ab ')2 and Fab fragments in nude mice. Data Archiving and Networked Services (DANS).

10.

Bruyn, Marco de, Yunwei Wei, Valerie R. Wiersma, et al.. (2011). Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells. Clinical Cancer Research. 17(17). 5626–5637. 33 indexed citations

11.

Lütje, Susanne, Otto C. Boerman, J.P. Michiel Sedelaar, et al.. (2011). Prospects in radionuclide imaging of prostate cancer. The Prostate. 72(11). 1262–1272. 24 indexed citations

12.

Zheng, Yu, et al.. (2010). A Novel I-123-Cubane Labelled Bombesin for Imaging GRP Receptor-Expressing Prostate Cancer Cells. Data Archiving and Networked Services (DANS). 1 indexed citations

13.

Bremer, Edwin, Marco de Bruyn, Douwe F. Samplonius, et al.. (2008). Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. Journal of Molecular Medicine. 86(8). 909–924. 26 indexed citations

14.

Sandovici, Maria, et al.. (2008). Systemic gene therapy with interleukin-13 attenuates renal ischemia–reperfusion injury. Kidney International. 73(12). 1364–1373. 32 indexed citations

15.

Stel, Alja J., Bram ten Cate, S. Jacobs, et al.. (2007). Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis. The Journal of Immunology. 178(4). 2287–2295. 69 indexed citations

16.

Bremer, Edwin, et al.. (2006). Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends in Molecular Medicine. 12(8). 382–393. 101 indexed citations

17.

Helfrich, Wijnand, Rob C. Roovers, Lidia Westers, et al.. (1998). Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. International Journal of Cancer. 76(2). 232–239. 40 indexed citations

18.

Helfrich, Wijnand, Rob C. Roovers, Lidia Westers, et al.. (1998). Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. International Journal of Cancer. 76(2). 232–239. 2 indexed citations

19.

Kroesen, Bart‐Jan, D.Th. Sleijfer, Grietje Molema, et al.. (1997). Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1. Cancer Immunology Immunotherapy. 45(3-4). 203–206. 27 indexed citations

20.

Malik, Afshan N., et al.. (1992). A discordance between the human muscle NCAM sequence and those seen in other NCAM cDNA clones. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1130(1). 95–96. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact